 |
|
|
| Home ->Aptamer screening | ||
| Quick Inquiry |
Aptamer Development Introduction Nucleic acid aptamers are short single-stranded oligonucleotides (ssDNA or ssRNA) that can selectively bind to a specific target with high affinity. A large number of aptamers have been developed to recognize various targets including small molecules, protein and entire cells. Aptamers have been widely used in both basic research and clinical purposes. The standard process used to screen aptamers is known as systematic evolution of ligands by exponential enrichment (SELEX). This process includes multiple rounds of incubation, separation, elution, amplification, and single-strand oligonucleotide purification and sequencing. RGBiotech has established an optimized platform for aptamer screening. We can select DNA aptamers against purified protein samples as well as small chemical molecules. We have successfully developed several aptamers with Kd affinity ranging from 0.1 ~ 10 nM. In most cases, more than one aptamer can be achieved through multiple rounds of selection. If the customer needs, we can provide all the aptamers obtained from the screening. Let RGBiotech assists you to promote progress in your aptamer-related research. 
Figure 1. Schematic process of SELEX Service Workflow How do we screen aptamers? This workflow could help you to understand the basic information.1) Synthesis of ssDNA library 2) Incubation of target and ssDNA library 3) Multiple rounds of washing – elution – PCR amplification 4) Sequencing 5) Detection of Kd affinity Features 1) The screening target covers purified protein and small chemical molecules.2) We can provide or purchase the target, so customers do not need to send us the sample. 3) The Kd affinity of aptamer is determined via capillary electrophoresis (CE). 4) Multiple aptamers could be available depending on the screening result. 5) We provide the selection protocol to let you know how the aptamer is gained. 6) Turnaround time: ~3 months Note: Currently, the success rate of our screening is approximately 80%. It is more difficult to screen aptamers against proteins in small size or small chemical molecules. We are always working hard to improve the screening efficiency. Final Delivered 1) At least one aptamer obtained with high affinity2) Plasmid containing the aptamer sequence 3) Screening report containing detailed target information, screening protocol, raw data, aptamer sequencing and affinity assay data. |
|
|
Products & Services Resources | ||
|
Home Products & Services Support About Us Contact Us |
Promotions Flyers Brochures Publications News & Events |
Terms & Conditions Privacy Disclaimers |
Contact Us EMAIL: admin@rgbiotech.com |
||
| © RGBiotech All Rights Reserved. | |||||